Amprologix attends International Biotechnology Achievement Forum in Riyadh
15 December 2025On 14th December, CSO Mat Upton was invited to attend the Final Forum of the Saudi Biotechnology Accelerator (SBA) in…
On 14th December, CSO Mat Upton was invited to attend the Final Forum of the Saudi Biotechnology Accelerator (SBA) in…
Amprologix celebrates research excellence at the University of Plymouth as CSO Professor Mat Upton presents the Research Excellence Award to…
Amprologix has raised £740,000 to accelerate the development of our breakthrough antibiotic Epidermicin NI01. This investment also supports our AI-driven…
We are pleased to announce that Professor Mat Upton, Chief Scientific Officer at Amprologix, will represent the company at the…
This summer we’ve been pleased to welcome Rutendo Mupfumi from the University of Plymouth to the Amprologix lab. As part…
October 2022 CSO Mat Upton joined 19 other start-ups that were selected from 700 applicants for a place at the Qatar Foundation WISH meeting on 4-6th October 2022.
April 2022 Gordon Barker, Amprologix CEO was selected to present our innovative antibiotic development approach at the Start-ups Session (https://amr-conference.com/start-ups-amr-conference-pitching-session/). The session, sponsored by INCATE and partners, was watched by potential investors and funders and included SMEs developing novel therapies through to vaccines and diagnostics.
January 2022 Amprologix and RefLab ApS (Copenhagen, Denmark) have collaborated on a project using an ex vivo human skin microdialysis model (below) to test pseudo-allergic reactions in the skin, without using animal models.
November 2021 Amprologix have contracted two leading Commercial Research Organisations to conduct pre-clinical work on lead compound, epidermicin NI01. Amprologix have contracted two leading Commercial Research Organisations to conduct pre-clinical work on lead compound, epidermicin NI01. A formulation was developed for delivery of NI01 to the nasal cavity and this was shown to retain antimicrobial […]
Amprologix CSO collaborates with Dr Max Ryadnov from the UK’s National Physical Laboratory, to publish new data on the novel mode of action of epidermicin NI01. Findings are reported in the August issue of iScience.
